Strategic Partnerships EpicentRx collaborates with other biotechs and foundations on grants and joint programs (e.g., MJFF, Shake It Up Australia, Fight MND; Actinium Pharmaceuticals collaboration; potential Actimab-A and CD47-SIRPα axis programs), signaling openness to co-development and combinatorial strategies that external partners can leverage for joint sales and access to broader networks.

Clinical Stage Advantage With lead therapies in Phase 3 (RRx-001) and Phase 2 (AdAPT-001) and a lead device (eLOOP), EpicentRx offers near-term inflection points for life sciences distributors, CROs, and contract manufacturers seeking late-stage opportunities or service collaborations around trial support, regulatory readiness, or adjuvant product integration.

Niche Focus A concentrated portfolio targeting cancer and inflammatory disorders with a focus on ease of treatment and tolerability appeals to specialty clinics and centers of excellence seeking patient-friendly therapies and devices, presenting a targeted entry point for sales teams to engage oncologists, neurodegenerative disease researchers, and translational medicine groups.

Funding Momentum Past and ongoing grants from MJFF and other foundations, plus SVB funding history, indicate strong investor interest and validating signals for funding-worthy collaborations, license deals, and co-funded trials that sales teams can frame as favorable financing and risk-sharing options for potential customers or partners.

Technology & IP Leverage EpicentRx combines a novel small molecule immunotherapy (RRx-001 nibrozetone) with an innovative oncolytic platform (AdAPT-001) and a medical device (eLOOP), creating a diversified cross-category value proposition that sales efforts can tailor to different stakeholders—from pharma partners and device distributors to research institutions seeking adjunctive therapies and niche tech enablement.